Related Experiment Videos
Effects of human sera on reactivity of lymphocytes in microcytotoxicity assays
Abstract:
The effects of cancer patient and normal donor serum samples on the reactivity of patient and normal lymphocytes against both normal and malignant target cells were studied in microcytotoxicity assays. There were 17 of 140 cancer patient serum samples and 7 of 116 normal donor lymphocyte samples that selectively increased the growth of target cells in the presence of lymphocytes. This effect was most often noted with cancer patient serum against cultured tumor cells, but the effect was also noted against fibroblasts and with normal serum against both fibroblasts and tumor cells. Of 140 cancer-patient serum samples, 11 selectively decreased target cell survival in the presence of lymphocytes compared to medium and compared to other serum samples. In the absence of lymphocytes these serum samples were nontoxic. The effect was not observed with any of the normal serum samples studied. The lymphocyte-dependent serum toxicity appeared to be selectively directed against tumor target cells.
Insights
Cancer patient serum samples can selectively decrease tumor cell survival in the presence of lymphocytes. This lymphocyte-dependent serum toxicity was not observed with normal serum samples, suggesting potential therapeutic applications.
Area of Science:
- Immunology
- Cancer Biology
- Cellular Immunology
Background:
- Investigating the interaction between patient/donor serum, lymphocytes, and target cells is crucial for understanding immune responses in cancer.
- Previous studies have explored serum effects on lymphocyte reactivity, but specific mechanisms and selective toxicity require further elucidation.
Purpose of the Study:
- To determine the effects of cancer patient and normal donor serum on lymphocyte reactivity against normal and malignant target cells.
- To identify serum samples exhibiting selective toxicity towards tumor cells in a lymphocyte-dependent manner.
Main Methods:
- Microcytotoxicity assays were employed to assess the impact of serum samples on target cell survival.
- Reactivity was evaluated using both cancer patient and normal donor serum and lymphocytes against normal and malignant target cells.
Main Results:
- 17 of 140 cancer patient serum samples and 7 of 116 normal donor samples selectively increased target cell growth with lymphocytes.
- 11 of 140 cancer patient serum samples demonstrated selective lymphocyte-dependent toxicity, decreasing target cell survival.
- This selective toxicity was specifically directed against tumor target cells and was not observed in the absence of lymphocytes or with normal serum samples.
Conclusions:
- Certain cancer patient serum samples possess the ability to induce lymphocyte-dependent toxicity selectively against tumor cells.
- These findings suggest a potential role for specific serum components in mediating anti-tumor immune responses.
- Further research into these serum-mediated effects could offer insights into novel cancer immunotherapies.